Publications by authors named "Aleksandra Chomakhidze"
Article Synopsis
- The study investigates the safety and effectiveness of canakinumab for patients with undifferentiated autoinflammatory diseases (uAIDs), which had not been previously assessed.
- Data from 32 uAID patients were analyzed, revealing a range of symptoms and prior treatments before starting canakinumab, including fever, rash, and various organ involvements.
- Results showed that 84% of patients achieved complete remission, while a smaller percentage had partial or no response to the treatment.
Background: A significant number of systemic juvenile idiopathic arthritis (sJIA) patients discontinue biologic disease-modifying antirheumatic drugs (bDMARDs) due to lack of efficacy or safety concerns. Studies of biologic therapy switch regimens in sJIA are required.
Methods: Patients with sJIA who switched from tocilizumab (due to lack of efficacy or safety) to canakinumab (4 mg/kg every 4 weeks) and were hospitalized at the rheumatology department from August 2012 to July 2020 were included.